This study utilized publicly available, de-identified data from the FDA Adverse Event Reporting System (FAERS), and therefore did not involve direct interaction with human participants or identifiable private information
Consider how long the pen has been unrefrigerated and whether it has been exposed to extreme heat, direct sunlight, or freezing conditions
Selectively increased necrosis in these xenografts
Traditional recovery methodssuch as ice baths, stretching, and protein intakehave their place, but many athletes are turning to more advanced tools to support performance and healing
Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
